Thyroid Eye Disease clinical trials at University of California Health

6 in progress, 3 open to eligible people

Showing trials for

  • Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease

    open to eligible people ages 18 years and up

    This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up observational period while off study drug. Some participants may also enter the open-label treatment period with efgartigimod PH20 SC. The study duration varies from approximately 60 to 110 weeks. An alternative list of clinical sites open for recruitment could be found in the other UplighTED study record (https://www.clinicaltrials.gov/study/NCT06307626)

    at UC Irvine

  • Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

    open to eligible people ages 18-80

    The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.

    at UCSD

  • Batoclimab in Participants With Active Thyroid Eye Disease

    open to eligible people ages 18 years and up

    To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

    at UCSF

  • Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

    Sorry, in progress, not accepting new patients

    The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).

    at UCLA UCSD

  • Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( THRIVE )

    Sorry, in progress, not accepting new patients

    Please note that Phase 1/2 (HV &amp ; TED MAD) cohorts and Phase 3 component (THRIVE) - recruitment is complete. The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of veligrotug (VRDN-001) in healthy volunteers (HV) and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.

    at UCSF

  • Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).

    at UCSD

Our lead scientists for Thyroid Eye Disease research studies include .

Last updated: